01
Cash & equivalents increased 34.5%
Cash & equivalents changed +34.5% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
$24.0M→$32.3MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTASSEMBLY BIOSCIENCES, INC.'s latest supported as-filed period reports revenue of $72.3M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +34.5% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Net income changed +62.2% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating income changed +42.8% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
ASMB · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-352193SEC ↗10-QAug 13, 2026Period Jun 30, 20260001193125-26-349236SEC ↗8-KAug 13, 2026Period Aug 13, 20260001193125-26-349198SEC ↗4Jun 18, 2026Period Jun 17, 20260001193125-26-275804SEC ↗4Jun 5, 2026Period Mar 29, 20260001193125-26-259927SEC ↗4Jun 5, 2026Period Mar 29, 20260001193125-26-259924SEC ↗4Jun 5, 2026Period Jun 4, 20260001193125-26-259855SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jun 17, 2026Filed Jun 18, 2026 | Bjorkquist Jeanette MPFO and PAO | Open Market SaleDirect | 29 | $23 | $674 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -7.5% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Stock-based compensation changed +189.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-259822